GSK targets $2.52 billion in savings by 2029 to accelerate drug pipeline

GSK Plc launched a cost-saving plan targeting $2.52 billion in annual savings by 2029, as Chief Executive Officer Luke Miels outlined his roadmap to accelerate the drugmaker's pipeline and hit its 2031 sales target.

"The savings will be reinvested into our most promising R&D programs, particularly in oncology and respiratory diseases," Miels said in a statement Tuesday.

The plan comes alongside GSK's second-quarter results, which beat profit estimates. The British drugmaker reported adjusted earnings that topped analyst expectations, though the company did not disclose specific quarterly revenue or EPS figures in the cost-saving announcement.

GSK also committed to investing 400 million pounds ($531 million) over three years in the UK, including a new 300,000-square-foot research and development center in Cambridge. The facility will house more than 1,000 scientists focused on cancer and respiratory drug development. The company plans to vacate its Stevenage R&D site by 2029 and upgrade its Ware facility, relocating some staff.

The cost-saving initiative targets operational efficiencies across manufacturing, supply chain, and administrative functions. GSK spends more than 6 billion pounds ($7.97 billion) annually on R&D, with over 1.5 billion pounds ($1.99 billion) of that in the UK.

The restructuring follows a U.S.-UK pharmaceutical trade deal finalized in April that raised medicine prices in Britain in line with new U.S. pricing policies under President Donald Trump. Rival AstraZeneca Plc announced a 300 million pound ($398 million) UK investment earlier this year after reversing a pause on large-scale projects.

Miels, who took the helm earlier this year, faces pressure to reinvigorate GSK's drug pipeline after years of underperformance relative to peers. The company's 2031 sales target implies a compound annual growth rate that would require successful launches of several late-stage candidates.

The savings plan signals management's confidence in its pipeline strategy, with key catalysts including upcoming Phase 3 readouts in oncology and respiratory medicine. Investors will watch for further details on pipeline milestones at GSK's R&D day later this year.

This article is for informational purposes only and does not constitute investment advice.